Characteristics | Cohort description | Total (n = 350) | |
---|---|---|---|
TMA-30 (n = 29) | TMA-2020 NO.1-8 (n = 321) | ||
Age, years | Â | Â | Â |
  Mean±SD | 60.3 ± 10.9 | 57.0 ± 11.9 | 57.2 ± 11.9 |
  Median | 63 | 55 | 56 |
  Range | 39–80 | 23–86 | 23–86 |
Sex, n (%) | Â | Â | Â |
  Male | 24 (82.8) | 224 (69.8) | 248 (70.9) |
  Female | 5 (17.2) | 97 (30.2) | 102 (29.1) |
Fuhrman grade, n (%) | Â | Â | Â |
  1–2 | 18 (62.1) | 261 (81.3) | 279 (79.7) |
  3–4 | 11 (37.9) | 60 (18.7) | 71 (20.3) |
TNM stage, n (%) | Â | Â | Â |
  I–II | 23 (79.3) | 275 (85.7) | 298 (85.1) |
  III–IV | 6 (20.7) | 45 (14.0) | 51 (14.6) |
  NA | 0 | 1 (0.3) | 1 (0.3) |
T category, n (%) | Â | Â | Â |
  T1a–T1b | 19 (65.5) | 252 (50.5) | 271 (77.4) |
  T2a–T4 | 10 (34.5) | 68 (49.2) | 78 (22.3) |
  NA | 0 | 1 (0.3) | 1 (0.3) |
Overall survival, n (%) | Â | Â | Â |
  − | 2 (6.9) | 249 (77.6) | 251 (71.7) |
  + | 27 (93.1) | 17 (5.3) | 44 (12.6) |
  NA | 0 | 55 (17.1) | 55 (15.7) |
Progression-free survival, n (%) | Â | Â | |
  − | 5 (17.2) | 236 (73.5) | 241 (68.9) |
  + | 24 (82.8) | 30 (9.3) | 54 (15.4) |
  NA | 0 | 55 (17.1) | 55 (15.7) |